101 related articles for article (PubMed ID: 3679793)
1. Selective right ventricular dysfunction following doxorubicin therapy.
Sperber AD; Cantor AA; Biran H; Keynan A
Isr J Med Sci; 1987 Aug; 23(8):896-9. PubMed ID: 3679793
[TBL] [Abstract][Full Text] [Related]
2. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies.
Carrió I; Lopez-Pousa A; Estorch M; Duncker D; Berná L; Torres G; de Andrés L
J Nucl Med; 1993 Sep; 34(9):1503-7. PubMed ID: 8355070
[TBL] [Abstract][Full Text] [Related]
3. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.
Alexander J; Dainiak N; Berger HJ; Goldman L; Johnstone D; Reduto L; Duffy T; Schwartz P; Gottschalk A; Zaret BL
N Engl J Med; 1979 Feb; 300(6):278-83. PubMed ID: 759880
[TBL] [Abstract][Full Text] [Related]
4. Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance.
Choi BW; Berger HJ; Schwartz PE; Alexander J; Wackers FJ; Gottschalk A; Zaret BL
Am Heart J; 1983 Oct; 106(4 Pt 1):638-43. PubMed ID: 6613807
[TBL] [Abstract][Full Text] [Related]
5. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.
Schwartz RG; McKenzie WB; Alexander J; Sager P; D'Souza A; Manatunga A; Schwartz PE; Berger HJ; Setaro J; Surkin L
Am J Med; 1987 Jun; 82(6):1109-18. PubMed ID: 3605130
[TBL] [Abstract][Full Text] [Related]
6. Radionuclide ejection fraction in doxorubicin cardiotoxicity.
Morgan GW; McIlveen BM; Freedman A; Murray IP
Cancer Treat Rep; 1981; 65(7-8):629-38. PubMed ID: 7248982
[TBL] [Abstract][Full Text] [Related]
7. Prediction of the left ventricular ejection fraction response to doxorubicin using a multiple linear regression model.
Rabinovitch M; Suissa S; Stern J; Adam J; Mettauer B; Boileau G; Elstein J; Rouleau J
Can J Cardiol; 1989; 5(8):382-8. PubMed ID: 2605548
[TBL] [Abstract][Full Text] [Related]
8. Radionuclide ventriculography for evaluation and prevention of doxorubicin cardiotoxicity.
Steinberg JS; Wasserman AG
Clin Ther; 1985; 7(6):660-7. PubMed ID: 3907840
[TBL] [Abstract][Full Text] [Related]
9. Gated blood pool scintigraphic monitoring of doxorubicin cardiomyopathy: comparison of camera and computerized probe results in 101 patients.
Strashun AM; Goldsmith SJ; Horowitz SF
J Am Coll Cardiol; 1986 Nov; 8(5):1082-7. PubMed ID: 3760382
[TBL] [Abstract][Full Text] [Related]
10. Reversible doxorubicin-induced congestive heart failure.
Cohen M; Kronzon I; Lebowitz A
Arch Intern Med; 1982 Aug; 142(8):1570-1. PubMed ID: 7103641
[TBL] [Abstract][Full Text] [Related]
11. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.
Cardinale D; Colombo A; Bacchiani G; Tedeschi I; Meroni CA; Veglia F; Civelli M; Lamantia G; Colombo N; Curigliano G; Fiorentini C; Cipolla CM
Circulation; 2015 Jun; 131(22):1981-8. PubMed ID: 25948538
[TBL] [Abstract][Full Text] [Related]
12. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
13. Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography.
Palmeri ST; Bonow RO; Myers CE; Seipp C; Jenkins J; Green MV; Bacharach SL; Rosenberg SA
Am J Cardiol; 1986 Sep; 58(7):607-13. PubMed ID: 3751931
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era.
Mitani I; Jain D; Joska TM; Burtness B; Zaret BL
J Nucl Cardiol; 2003; 10(2):132-9. PubMed ID: 12673177
[TBL] [Abstract][Full Text] [Related]
15. Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer.
Estorch M; Carrió I; Berná L; Martínez-Duncker C; Alonso C; Germá JR; Ojeda B
J Nucl Med; 1990 Dec; 31(12):1965-9. PubMed ID: 2266394
[TBL] [Abstract][Full Text] [Related]
16. Adriamycin (doxorubicin) cardiotoxicity: a review.
Chlebowski RT
West J Med; 1979 Nov; 131(5):364-8. PubMed ID: 394479
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients.
Nousiainen T; Vanninen E; Jantunen E; Remes J; Ritanen E; Vuolteenaho O; Hartikainen J
Clin Sci (Lond); 2001 Dec; 101(6):601-7. PubMed ID: 11724646
[TBL] [Abstract][Full Text] [Related]
18. Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
Klein JL; Rey PM; Dansey RD; Karanes C; Du W; Abella E; Cassells L; Hamm C; Peters WP; Baynes RD
Bone Marrow Transplant; 2000 May; 25(10):1047-52. PubMed ID: 10828864
[TBL] [Abstract][Full Text] [Related]
19. [Changes in left ventricular function during chemotherapy with doxorubicin].
Elbl L; Chaloupka V; Vásová I; Kiss I; Jancík J; Vorlícek J; Navrátil M
Vnitr Lek; 1999 Jul; 45(7):395-402. PubMed ID: 11045157
[TBL] [Abstract][Full Text] [Related]
20. Assessment of ventricular function by radionuclide angiography in patients receiving 4'-epidoxorubicin and mitoxantrone.
Vorobiof DA; Iturralde M; Falkson G
Cancer Chemother Pharmacol; 1985; 15(3):253-7. PubMed ID: 3863718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]